MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 464327 | Name: Efinaconazole-d4
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Efinaconazole-d4 is intended for use as an internal standard for the quantification of efinaconazole by GC- or LC-MS. Efinaconazole is a broad-spectrum triazole antifungal agent with activity against Acremonium, Aspergillus, Candida, Cryptococcus, Epidermophyton, Fusarium, Microsporum, Paecilomyces, Pseudallescheria, Scopulariopsis, Trichophyton, and Trichosporon. It inhibits the growth of T. rubrum and T. mentagrophytes clinical isolates with MIC values ranging from ≤2.0 to 60 ng/ml and of C. albicans isolates with MIC values ranging from ≤0.5 to >250 ng/ml. Efinaconazole inhibits sterol 14α-demethylase, which arrests ergosterol biosynthesis at the fungal membrane. It inhibits ergosterol biosynthesis in T. mentagrophytes and C. albicans with IC50 values of 7.0 and 0.40 ng/ml, respectfully. Topical formulations containing efinaconazole have been used for the treatment of onychomycosis.

Chemical Structure

Efinaconazole-d4
Efinaconazole-d4
CAS#Efinaconazole-d4

Theoretical Analysis

MedKoo Cat#: 464327

Name: Efinaconazole-d4

CAS#: Efinaconazole-d4

Chemical Formula: C18H18D4F2N4O

Exact Mass: 352.2013

Molecular Weight: 352.42

Elemental Analysis: C, 61.35; H, 7.43; F, 10.78; N, 15.90; O, 4.54

Price and Availability

Size Price Availability Quantity
1mg USD 550.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
Efinaconazole-d4 164650-44-6
Synonym
Efinaconazole-d4; Efinaconazole d4;
IUPAC/Chemical Name
(2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl-2,2,6,6-d4)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol
InChi Key
NFEZZTICAUWDHU-INFILRCQSA-N
InChi Code
InChI=1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1/i7D2,8D2
SMILES Code
C=C1CC([2H])(N(C([2H])(C1)[2H])[C@H](C)[C@](C2=CC=C(C=C2F)F)(O)CN3C=NC=N3)[2H]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
Acetonitrile 0.0 0.00
Methanol 0.0 0.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 352.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Agrawal V, Patel R, Patel M, Thanki K, Mishra S. Design and evaluation of microemulsion-based efinaconazole formulations for targeted treatment of onychomycosis through transungual route: Ex vivo and nail clipping studies. Colloids Surf B Biointerfaces. 2021 Feb 19;201:111652. doi: 10.1016/j.colsurfb.2021.111652. Epub ahead of print. PMID: 33740733. 2: Nakamura A, Hirakawa S, Nagai H, Inagaki K. A comparative study between two antifungal agents, Luliconazole and Efinaconazole, of their preventive effects in a Trichophyton-infected guinea pig onychomycosis model. Med Mycol. 2021 Mar 4;59(3):289-295. doi: 10.1093/mmy/myaa111. PMID: 33539539; PMCID: PMC7939111. 3: Gupta AK, Cooper EA. Long-term Efficacy and Safety of Once-daily Efinaconazole 10% Topical Solution (Jublia) for Dermatophyte Toenail Onychomycosis: An Interim Analysis. Skin Therapy Lett. 2021 Jan;26(1):5-10. PMID: 33539062. 4: Geizhals S, Lipner SR. A Timeline of Onychomycosis Therapy and Future Directions. Skinmed. 2020 Dec 1;18(6):367-371. PMID: 33397567. 5: Hirose M, Noguchi H, Matsumoto T, Kimura U, Hiruma M, Kano R, Yaguchi T, Fujimoto N, Satoh T, Ihn H. Ungual hyalohyphomycosis caused by Fusarium cugenangense. Clin Case Rep. 2020 Nov 5;8(12):3533-3538. doi: 10.1002/ccr3.2941. PMID: 33363967; PMCID: PMC7752399. 6: Eichenfield LF, Elewski B, Sugarman JL, Rosen T, Vlahovic TC, Gupta AK, Stein Gold L, Pillai R, Guenin E. Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients. J Drugs Dermatol. 2020 Sep 1;19(9):867-872. doi: 10.36849/JDD.2020.10.36849/JDD.2020.5401. PMID: 33026753. 7: Garcia LM, Costa-Orlandi CB, Bila NM, Vaso CO, Gonçalves LNC, Fusco-Almeida AM, Mendes-Giannini MJS. A Two-Way Road: Antagonistic Interaction Between Dual- Species Biofilms Formed by Candida albicans/Candida parapsilosis and Trichophyton rubrum. Front Microbiol. 2020 Sep 4;11:1980. doi: 10.3389/fmicb.2020.01980. PMID: 33013741; PMCID: PMC7499241. 8: Ricardo JW, Lipner SR. Safety of current therapies for onychomycosis. Expert Opin Drug Saf. 2020 Nov;19(11):1395-1408. doi: 10.1080/14740338.2020.1829592. Epub 2020 Oct 12. PMID: 32990062. 9: Fujimoto K, Yamaguchi H, Otsuka Y, Mayumi N, Saeki H. Contact dermatitis caused by efinaconazole and luliconazole. J Nippon Med Sch. 2020 Aug 31. doi: 10.1272/jnms.JNMS.2021_88-312. Epub ahead of print. PMID: 32863343. 10: Gupta AK, Venkataraman M, Shear NH, Piguet V. Onychomycosis in children - review on treatment and management strategies. J Dermatolog Treat. 2020 Aug 26:1-12. doi: 10.1080/09546634.2020.1810607. Epub ahead of print. PMID: 32799713. 11: Komatsu-Fujii T, Nonoyama S, Ogawa M, Fukumoto T, Ookura T, Anzawa K, Abe N, Tanabe H. Usefulness of topical efinaconazole for infantile tinea capitis due to Microsporum canis diagnosed with Wood's light. J Dermatol. 2020 Nov;47(11):e401-e403. doi: 10.1111/1346-8138.15555. Epub 2020 Aug 13. PMID: 32794269. 12: Chen YH, Chi MJ, Sun PL, Yu PH, Liu CH, Cano-Lira JF, Li WT. Histopathology, Molecular Identification and Antifungal Susceptibility Testing of Nannizziopsis arthrosporioides from a Captive Cuban Rock Iguana (Cyclura nubila). Mycopathologia. 2020 Dec;185(6):1005-1012. doi: 10.1007/s11046-020-00481-6. Epub 2020 Aug 13. PMID: 32794052. 13: Piraccini BM, Iorizzo M, Lencastre A, Nenoff P, Rigopoulos D. Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis. Dermatol Ther (Heidelb). 2020 Oct;10(5):917-929. doi: 10.1007/s13555-020-00420-9. Epub 2020 Jul 23. PMID: 32705532; PMCID: PMC7477053. 14: Irannejad H, Emami S, Mirzaei H, Hashemi SM. Data on molecular docking of tautomers and enantiomers of ATTAF-1 and ATTAF-2 selectivty to the human/fungal lanosterol-14α-demethylase. Data Brief. 2020 Jun 27;31:105942. doi: 10.1016/j.dib.2020.105942. PMID: 32671150; PMCID: PMC7341365. 15: Eichenfield LF, Elewski B, Sugarman JL, Rosen T, Vlahovic TC, Gupta AK, Pillai R, Guenin E. Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study. J Am Acad Dermatol. 2021 Apr;84(4):1140-1142. doi: 10.1016/j.jaad.2020.06.1004. Epub 2020 Jul 2. PMID: 32622145. 16: Stewart CR, Algu L, Kamran R, Leveille CF, Abid K, Rae C, Lipner SR. Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review. J Am Acad Dermatol. 2020 Jun 2:S0190-9622(20)31020-3. doi: 10.1016/j.jaad.2020.05.143. Epub ahead of print. PMID: 32502586. 17: Gupta AK, Venkataraman M, Shear NH, Piguet V. Labeled use of efinaconazole topical solution 10% in treating onychomycosis in children and a review of the management of pediatric onychomycosis. Dermatol Ther. 2020 Jul;33(4):e13613. doi: 10.1111/dth.13613. Epub 2020 Jul 18. PMID: 32418289. 18: Wu AG, Geizhals S, Lipner SR. Retrospective study of factors affecting medication adherence in patients prescribed efinaconazole 10% solution for onychomycosis. J Am Acad Dermatol. 2021 Jan;84(1):208-210. doi: 10.1016/j.jaad.2020.04.126. Epub 2020 Apr 30. PMID: 32360855. 19: Gupta AK, Stec N, Summerbell RC, Shear NH, Piguet V, Tosti A, Piraccini BM. Onychomycosis: a review. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1972-1990. doi: 10.1111/jdv.16394. Epub 2020 Jun 5. PMID: 32239567. 20: Taghipour S, Shamsizadeh F, Pchelin IM, Rezaei-Matehhkolaei A, Zarei Mahmoudabadi A, Valadan R, Ansari S, Katiraee F, Pakshir K, Zomorodian K, Abastabar M. Emergence of Terbinafine Resistant Trichophyton mentagrophytes in Iran, Harboring Mutations in the Squalene Epoxidase (SQLE) Gene. Infect Drug Resist. 2020 Mar 13;13:845-850. doi: 10.2147/IDR.S246025. PMID: 32214830; PMCID: PMC7078656.